Share Price and Basic Stock Data
Last Updated: January 9, 2026, 2:35 am
| PEG Ratio | -6.14 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Camlin Fine Sciences Ltd, operating in the specialty chemicals sector, reported a share price of ₹151 and a market capitalization of ₹2,898 Cr. The company’s sales for the fiscal year ending March 2023 stood at ₹1,682 Cr, reflecting a consistent increase from ₹1,412 Cr in March 2022. However, sales for the trailing twelve months (TTM) reached ₹1,752 Cr, indicating some fluctuations in revenue generation. Quarterly sales showed variability, with the highest quarterly sales of ₹483 Cr recorded in September 2022, declining to ₹388 Cr in December 2022, and stabilizing around the ₹400 Cr mark in subsequent quarters. The operating profit margin (OPM) was relatively low at 7% for the TTM, with a notable drop to 6% in September 2023. This trend underscores the challenges faced in maintaining consistent revenue growth amidst fluctuating operational performance.
Profitability and Efficiency Metrics
Camlin reported a net profit of ₹-33 Cr in the TTM, reflecting a significant decline from the previous fiscal when net profit was ₹40 Cr. The operating profit for the year stood at ₹220 Cr, with a corresponding OPM of 13% for March 2025. The company’s return on equity (ROE) was 15.0%, while return on capital employed (ROCE) was 11.0%, indicating moderate efficiency in utilizing shareholder funds. However, the interest coverage ratio (ICR) of 2.23x suggests that the company is facing challenges in covering its interest obligations, especially with total borrowings reported at ₹672 Cr. The cash conversion cycle (CCC) of 143 days indicates extended periods before converting investments into cash, which can strain liquidity. Overall, while there are some positive indicators of profitability, the net losses and declining profit margins raise concerns about operational sustainability.
Balance Sheet Strength and Financial Ratios
Camlin’s balance sheet reflects a total debt of ₹672 Cr against reserves of ₹871 Cr, signifying a reasonable level of leverage with a debt-to-equity ratio of 0.71x. The current ratio stood at 1.40, indicating adequate short-term liquidity, while the quick ratio of 0.77 suggests potential liquidity risks if immediate obligations arise. The book value per share, excluding revaluation reserves, was reported at ₹47.81. The price-to-book value ratio was 3.51x, indicating that the stock is trading at a premium compared to its book value, which may be a concern for value investors. The company’s return on assets (ROA) was reported at -6.87%, reflecting inefficiencies in asset utilization. Despite these challenges, the company retains a substantial asset base of ₹2,037 Cr, which includes fixed assets valued at ₹700 Cr, providing a foundation for operational activities.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Camlin Fine Sciences reveals a significant presence of promoters, holding 48.03% of the company as of September 2023. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), held 2.14% and 7.77% respectively, reflecting modest institutional interest. The public shareholding stood at 42.04%, with a total of 52,845 shareholders. The gradual increase in promoter holdings from 17.64% in March 2023 to current levels indicates growing confidence among company insiders. Conversely, the reduction in FIIs from 10.18% in March 2023 to 1.61% in September 2023 raises concerns about external investor sentiment. This mixed ownership structure may influence future capital raising efforts and overall market perception, highlighting the need for improved financial performance to attract a broader investor base.
Outlook, Risks, and Final Insight
Looking ahead, Camlin Fine Sciences faces a dual-edged scenario. On one hand, the company has opportunities to enhance its operational efficiency and profitability, particularly by addressing its high cash conversion cycle and improving its interest coverage ratio. On the other hand, persistent net losses pose significant risks to its financial health and investor confidence. The decline in quarterly profits and fluctuating sales figures suggest potential volatility in revenue generation. If these trends continue, the company may struggle to maintain its current market capitalization and attract further investment. Conversely, a focus on operational improvements, increased efficiency, and strategic growth initiatives could reverse the current trajectory, leading to a more stable financial outlook. The balance between these factors will determine Camlin’s future performance in the specialty chemicals sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 371 Cr. | 40.6 | 78.8/40.0 | 23.0 | 20.5 | 0.99 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 29.0 Cr. | 59.1 | 88.8/55.0 | 13.9 | 89.6 | 1.69 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 46.8 Cr. | 688 | 918/600 | 21.6 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,431 Cr. | 75.7 | 111/68.2 | 22.7 | 22.0 | 0.66 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 614 Cr. | 246 | 393/230 | 22.0 | 93.8 | 1.02 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,890.24 Cr | 707.20 | 66.15 | 183.02 | 0.45% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 483 | 388 | 427 | 420 | 406 | 386 | 377 | 381 | 417 | 431 | 437 | 424 | 460 |
| Expenses | 428 | 338 | 383 | 381 | 381 | 363 | 345 | 352 | 366 | 375 | 378 | 405 | 427 |
| Operating Profit | 55 | 50 | 44 | 39 | 25 | 23 | 31 | 29 | 52 | 56 | 59 | 19 | 33 |
| OPM % | 11% | 13% | 10% | 9% | 6% | 6% | 8% | 8% | 12% | 13% | 14% | 4% | 7% |
| Other Income | 3 | 10 | -8 | 6 | 2 | 2 | -96 | -15 | -151 | -8 | -17 | 3 | -4 |
| Interest | 18 | 12 | 10 | 10 | 20 | 14 | 16 | 23 | 26 | 34 | 16 | 16 | 19 |
| Depreciation | 14 | 16 | 18 | 19 | 19 | 21 | 13 | 15 | 17 | 14 | 18 | 17 | 19 |
| Profit before tax | 26 | 32 | 8 | 16 | -12 | -10 | -94 | -23 | -142 | -0 | 8 | -11 | -9 |
| Tax % | 61% | 28% | 59% | 25% | 72% | 47% | -13% | 48% | -18% | 2,164% | 99% | -0% | 65% |
| Net Profit | 10 | 23 | 3 | 12 | -21 | -14 | -82 | -35 | -116 | -7 | 0 | -11 | -15 |
| EPS in Rs | 0.74 | 1.36 | 0.52 | 0.83 | -1.03 | -0.63 | -4.11 | -1.81 | -5.33 | -0.22 | -0.04 | -0.53 | -0.76 |
Last Updated: January 2, 2026, 4:03 am
Below is a detailed analysis of the quarterly data for Camlin Fine Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 460.00 Cr.. The value appears strong and on an upward trend. It has increased from 424.00 Cr. (Jun 2025) to 460.00 Cr., marking an increase of 36.00 Cr..
- For Expenses, as of Sep 2025, the value is 427.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 405.00 Cr. (Jun 2025) to 427.00 Cr., marking an increase of 22.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 33.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Jun 2025) to 33.00 Cr., marking an increase of 14.00 Cr..
- For OPM %, as of Sep 2025, the value is 7.00%. The value appears strong and on an upward trend. It has increased from 4.00% (Jun 2025) to 7.00%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is -4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Jun 2025) to -4.00 Cr., marking a decrease of 7.00 Cr..
- For Interest, as of Sep 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16.00 Cr. (Jun 2025) to 19.00 Cr., marking an increase of 3.00 Cr..
- For Depreciation, as of Sep 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.00 Cr. (Jun 2025) to 19.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -9.00 Cr.. The value appears strong and on an upward trend. It has increased from -11.00 Cr. (Jun 2025) to -9.00 Cr., marking an increase of 2.00 Cr..
- For Tax %, as of Sep 2025, the value is 65.00%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Jun 2025) to 65.00%, marking an increase of 65.00%.
- For Net Profit, as of Sep 2025, the value is -15.00 Cr.. The value appears to be declining and may need further review. It has decreased from -11.00 Cr. (Jun 2025) to -15.00 Cr., marking a decrease of 4.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.76. The value appears to be declining and may need further review. It has decreased from -0.53 (Jun 2025) to -0.76, marking a decrease of 0.23.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:31 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 509 | 558 | 489 | 534 | 721 | 892 | 1,049 | 1,187 | 1,412 | 1,682 | 1,454 | 1,667 | 1,752 |
| Expenses | 446 | 474 | 397 | 502 | 705 | 819 | 914 | 1,000 | 1,254 | 1,468 | 1,284 | 1,447 | 1,584 |
| Operating Profit | 63 | 84 | 92 | 32 | 16 | 73 | 135 | 187 | 158 | 213 | 170 | 220 | 167 |
| OPM % | 12% | 15% | 19% | 6% | 2% | 8% | 13% | 16% | 11% | 13% | 12% | 13% | 10% |
| Other Income | 9 | 9 | -1 | 14 | 12 | 14 | 3 | 5 | 33 | -4 | -142 | -203 | -26 |
| Interest | 25 | 24 | 24 | 31 | 32 | 41 | 48 | 42 | 41 | 66 | 70 | 111 | 85 |
| Depreciation | 12 | 16 | 17 | 22 | 27 | 29 | 33 | 44 | 56 | 63 | 56 | 64 | 69 |
| Profit before tax | 35 | 53 | 50 | -6 | -31 | 17 | 58 | 105 | 94 | 80 | -99 | -158 | -12 |
| Tax % | 18% | -4% | 28% | -26% | -22% | 82% | 49% | 38% | 36% | 50% | 6% | 0% | |
| Net Profit | 29 | 55 | 36 | -4 | -24 | 3 | 30 | 65 | 60 | 40 | -105 | -158 | -33 |
| EPS in Rs | 2.71 | 5.11 | 3.30 | -0.96 | -2.18 | 0.04 | 2.23 | 3.56 | 3.45 | 2.96 | -4.94 | -7.40 | -1.55 |
| Dividend Payout % | 12% | 8% | 12% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 89.66% | -34.55% | -111.11% | -500.00% | 112.50% | 900.00% | 116.67% | -7.69% | -33.33% | -362.50% | -50.48% |
| Change in YoY Net Profit Growth (%) | 0.00% | -124.20% | -76.57% | -388.89% | 612.50% | 787.50% | -783.33% | -124.36% | -25.64% | -329.17% | 312.02% |
Camlin Fine Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 223% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 20% |
| 3 Years: | 19% |
| 1 Year: | 103% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -2% |
| 3 Years: | -7% |
| Last Year: | -15% |
Last Updated: September 5, 2025, 1:30 am
Balance Sheet
Last Updated: December 10, 2025, 2:30 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 10 | 10 | 12 | 12 | 12 | 13 | 16 | 16 | 17 | 19 | 19 |
| Reserves | 84 | 125 | 167 | 202 | 359 | 359 | 391 | 631 | 732 | 804 | 848 | 883 | 871 |
| Borrowings | 150 | 160 | 180 | 331 | 373 | 461 | 539 | 550 | 646 | 801 | 683 | 681 | 672 |
| Other Liabilities | 126 | 131 | 123 | 126 | 273 | 255 | 290 | 282 | 396 | 425 | 424 | 454 | 476 |
| Total Liabilities | 369 | 426 | 479 | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,037 | 2,037 |
| Fixed Assets | 83 | 106 | 140 | 201 | 278 | 272 | 306 | 584 | 601 | 858 | 816 | 704 | 700 |
| CWIP | 22 | 3 | 25 | 8 | 14 | 59 | 179 | 24 | 215 | 43 | 46 | 10 | 15 |
| Investments | 1 | 1 | 1 | 19 | 115 | 11 | 7 | 7 | 7 | 8 | 8 | 61 | 69 |
| Other Assets | 262 | 316 | 313 | 442 | 609 | 745 | 740 | 861 | 966 | 1,136 | 1,102 | 1,262 | 1,253 |
| Total Assets | 369 | 426 | 479 | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,037 | 2,037 |
Below is a detailed analysis of the balance sheet data for Camlin Fine Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 19.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 19.00 Cr..
- For Reserves, as of Sep 2025, the value is 871.00 Cr.. The value appears to be declining and may need further review. It has decreased from 883.00 Cr. (Mar 2025) to 871.00 Cr., marking a decrease of 12.00 Cr..
- For Borrowings, as of Sep 2025, the value is 672.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 681.00 Cr. (Mar 2025) to 672.00 Cr., marking a decrease of 9.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 476.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 454.00 Cr. (Mar 2025) to 476.00 Cr., marking an increase of 22.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,037.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2,037.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 700.00 Cr.. The value appears to be declining and may need further review. It has decreased from 704.00 Cr. (Mar 2025) to 700.00 Cr., marking a decrease of 4.00 Cr..
- For CWIP, as of Sep 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2025) to 15.00 Cr., marking an increase of 5.00 Cr..
- For Investments, as of Sep 2025, the value is 69.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Mar 2025) to 69.00 Cr., marking an increase of 8.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,253.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,262.00 Cr. (Mar 2025) to 1,253.00 Cr., marking a decrease of 9.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,037.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2,037.00 Cr..
Notably, the Reserves (871.00 Cr.) exceed the Borrowings (672.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -87.00 | -76.00 | -88.00 | -299.00 | -357.00 | -388.00 | -404.00 | -363.00 | -488.00 | -588.00 | -513.00 | -461.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73 | 74 | 56 | 99 | 104 | 86 | 88 | 83 | 77 | 66 | 72 | 72 |
| Inventory Days | 145 | 184 | 311 | 277 | 207 | 219 | 204 | 200 | 178 | 255 | 256 | 233 |
| Days Payable | 132 | 144 | 171 | 110 | 154 | 127 | 119 | 99 | 112 | 129 | 154 | 162 |
| Cash Conversion Cycle | 85 | 114 | 196 | 266 | 157 | 178 | 173 | 184 | 143 | 192 | 174 | 143 |
| Working Capital Days | -4 | 12 | 1 | -6 | 19 | 43 | 22 | 55 | 40 | 42 | 51 | 35 |
| ROCE % | 28% | 28% | 24% | 5% | 0% | 7% | 11% | 13% | 10% | 10% | 8% | 11% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Commodities Fund | 4,624,431 | 2.41 | 76.27 | 2,957,188 | 2025-12-15 01:00:05 | 56.38% |
| Franklin India Opportunities Fund | 3,135,785 | 0.62 | 51.72 | 2,764,166 | 2025-12-15 01:00:05 | 13.44% |
| ICICI Prudential Multicap Fund | 2,665,909 | 0.27 | 43.97 | 1,802,309 | 2025-12-15 01:00:05 | 47.92% |
| JM Aggressive Hybrid Fund | 554,131 | 1.13 | 9.14 | 704,131 | 2025-12-15 01:00:05 | -21.3% |
| ICICI Prudential Retirement Fund - Pure Equity | 313,993 | 0.33 | 5.18 | N/A | N/A | N/A |
| ICICI Prudential MidCap Fund | 82,527 | 0.02 | 1.36 | N/A | N/A | N/A |
| ICICI Prudential Business Cycle Fund | 50,000 | 0.01 | 0.82 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -8.03 | -5.58 | 3.45 | 4.65 | 4.13 |
| Diluted EPS (Rs.) | -7.95 | -5.50 | 3.41 | 4.56 | 3.68 |
| Cash EPS (Rs.) | -5.04 | -1.57 | 6.51 | 7.42 | 8.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 47.81 | 48.29 | 48.18 | 43.26 | 47.81 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 47.81 | 50.97 | 52.25 | 48.52 | 55.67 |
| Revenue From Operations / Share (Rs.) | 88.68 | 96.32 | 107.04 | 89.95 | 93.11 |
| PBDIT / Share (Rs.) | 11.84 | 5.34 | 13.44 | 11.84 | 14.66 |
| PBIT / Share (Rs.) | 8.45 | 0.64 | 9.46 | 8.27 | 11.19 |
| PBT / Share (Rs.) | 2.61 | -5.93 | 5.12 | 5.99 | 8.24 |
| Net Profit / Share (Rs.) | -8.44 | -6.26 | 2.53 | 3.85 | 5.13 |
| NP After MI And SOA / Share (Rs.) | -7.40 | -5.54 | 3.32 | 3.87 | 4.00 |
| PBDIT Margin (%) | 13.35 | 5.54 | 12.55 | 13.16 | 15.74 |
| PBIT Margin (%) | 9.52 | 0.67 | 8.83 | 9.19 | 12.01 |
| PBT Margin (%) | 2.94 | -6.15 | 4.77 | 6.66 | 8.85 |
| Net Profit Margin (%) | -9.51 | -6.50 | 2.36 | 4.28 | 5.50 |
| NP After MI And SOA Margin (%) | -8.34 | -5.75 | 3.09 | 4.29 | 4.29 |
| Return on Networth / Equity (%) | -15.47 | -11.35 | 6.92 | 9.16 | 9.43 |
| Return on Capital Employeed (%) | 13.47 | 0.89 | 11.72 | 10.77 | 14.20 |
| Return On Assets (%) | -6.87 | -4.75 | 2.52 | 3.37 | 3.43 |
| Long Term Debt / Equity (X) | 0.29 | 0.40 | 0.54 | 0.58 | 0.50 |
| Total Debt / Equity (X) | 0.71 | 0.80 | 1.04 | 0.94 | 0.99 |
| Asset Turnover Ratio (%) | 0.83 | 0.80 | 0.46 | 0.48 | 0.52 |
| Current Ratio (X) | 1.40 | 1.37 | 1.37 | 1.50 | 1.66 |
| Quick Ratio (X) | 0.77 | 0.66 | 0.65 | 0.87 | 0.99 |
| Inventory Turnover Ratio (X) | 3.21 | 1.38 | 1.29 | 1.65 | 1.79 |
| Interest Coverage Ratio (X) | 2.23 | 1.48 | 3.61 | 5.20 | 4.98 |
| Interest Coverage Ratio (Post Tax) (X) | 1.59 | 0.08 | 1.85 | 2.69 | 2.74 |
| Enterprise Value (Cr.) | 3620.14 | 2050.95 | 2685.65 | 2687.50 | 2251.73 |
| EV / Net Operating Revenue (X) | 2.17 | 1.27 | 1.60 | 1.90 | 1.90 |
| EV / EBITDA (X) | 16.27 | 22.92 | 12.72 | 14.46 | 12.05 |
| MarketCap / Net Operating Revenue (X) | 1.89 | 0.92 | 1.19 | 1.55 | 1.50 |
| Price / BV (X) | 3.51 | 1.83 | 2.66 | 3.31 | 3.30 |
| Price / Net Operating Revenue (X) | 1.89 | 0.92 | 1.19 | 1.55 | 1.50 |
| EarningsYield | -0.04 | -0.06 | 0.02 | 0.02 | 0.02 |
After reviewing the key financial ratios for Camlin Fine Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -8.03. This value is below the healthy minimum of 5. It has decreased from -5.58 (Mar 24) to -8.03, marking a decrease of 2.45.
- For Diluted EPS (Rs.), as of Mar 25, the value is -7.95. This value is below the healthy minimum of 5. It has decreased from -5.50 (Mar 24) to -7.95, marking a decrease of 2.45.
- For Cash EPS (Rs.), as of Mar 25, the value is -5.04. This value is below the healthy minimum of 3. It has decreased from -1.57 (Mar 24) to -5.04, marking a decrease of 3.47.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 47.81. It has decreased from 48.29 (Mar 24) to 47.81, marking a decrease of 0.48.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 47.81. It has decreased from 50.97 (Mar 24) to 47.81, marking a decrease of 3.16.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 88.68. It has decreased from 96.32 (Mar 24) to 88.68, marking a decrease of 7.64.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.84. This value is within the healthy range. It has increased from 5.34 (Mar 24) to 11.84, marking an increase of 6.50.
- For PBIT / Share (Rs.), as of Mar 25, the value is 8.45. This value is within the healthy range. It has increased from 0.64 (Mar 24) to 8.45, marking an increase of 7.81.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from -5.93 (Mar 24) to 2.61, marking an increase of 8.54.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -8.44. This value is below the healthy minimum of 2. It has decreased from -6.26 (Mar 24) to -8.44, marking a decrease of 2.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -7.40. This value is below the healthy minimum of 2. It has decreased from -5.54 (Mar 24) to -7.40, marking a decrease of 1.86.
- For PBDIT Margin (%), as of Mar 25, the value is 13.35. This value is within the healthy range. It has increased from 5.54 (Mar 24) to 13.35, marking an increase of 7.81.
- For PBIT Margin (%), as of Mar 25, the value is 9.52. This value is below the healthy minimum of 10. It has increased from 0.67 (Mar 24) to 9.52, marking an increase of 8.85.
- For PBT Margin (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 10. It has increased from -6.15 (Mar 24) to 2.94, marking an increase of 9.09.
- For Net Profit Margin (%), as of Mar 25, the value is -9.51. This value is below the healthy minimum of 5. It has decreased from -6.50 (Mar 24) to -9.51, marking a decrease of 3.01.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -8.34. This value is below the healthy minimum of 8. It has decreased from -5.75 (Mar 24) to -8.34, marking a decrease of 2.59.
- For Return on Networth / Equity (%), as of Mar 25, the value is -15.47. This value is below the healthy minimum of 15. It has decreased from -11.35 (Mar 24) to -15.47, marking a decrease of 4.12.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.47. This value is within the healthy range. It has increased from 0.89 (Mar 24) to 13.47, marking an increase of 12.58.
- For Return On Assets (%), as of Mar 25, the value is -6.87. This value is below the healthy minimum of 5. It has decreased from -4.75 (Mar 24) to -6.87, marking a decrease of 2.12.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has decreased from 0.40 (Mar 24) to 0.29, marking a decrease of 0.11.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.71. This value is within the healthy range. It has decreased from 0.80 (Mar 24) to 0.71, marking a decrease of 0.09.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.83. It has increased from 0.80 (Mar 24) to 0.83, marking an increase of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 1.5. It has increased from 1.37 (Mar 24) to 1.40, marking an increase of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.77, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.21. This value is below the healthy minimum of 4. It has increased from 1.38 (Mar 24) to 3.21, marking an increase of 1.83.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.23. This value is below the healthy minimum of 3. It has increased from 1.48 (Mar 24) to 2.23, marking an increase of 0.75.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.59. This value is below the healthy minimum of 3. It has increased from 0.08 (Mar 24) to 1.59, marking an increase of 1.51.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,620.14. It has increased from 2,050.95 (Mar 24) to 3,620.14, marking an increase of 1,569.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.17. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 2.17, marking an increase of 0.90.
- For EV / EBITDA (X), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 15. It has decreased from 22.92 (Mar 24) to 16.27, marking a decrease of 6.65.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 1.89, marking an increase of 0.97.
- For Price / BV (X), as of Mar 25, the value is 3.51. This value exceeds the healthy maximum of 3. It has increased from 1.83 (Mar 24) to 3.51, marking an increase of 1.68.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 1.89, marking an increase of 0.97.
- For EarningsYield, as of Mar 25, the value is -0.04. This value is below the healthy minimum of 5. It has increased from -0.06 (Mar 24) to -0.04, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Camlin Fine Sciences Ltd:
- Net Profit Margin: -9.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.47% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -15.47% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.59
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 185 (Industry average Stock P/E: 66.15)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.71
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -9.51%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Floor 2 to 5, In GS Point, Mumbai Maharashtra 400098 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ashish Dandekar | Chairman & Managing Director |
| Mr. Nirmal Momaya | Managing Director |
| Mr. Arjun Dukane | Executive Director -Technical |
| Mr. Joseph Conrad D'souza | Independent Director |
| Ms. Anagha Dandekar | Non Exe.Non Ind.Director |
| Mr. Harsha Raghavan | Non Exe.Non Ind.Director |
| Mr. Jens Van Nieuwenborgh | Non Exe.Non Ind.Director |
| Mr. Mahabaleshwar Palekar | Independent Director |
| Mr. Pradip Kanakia | Independent Director |
| Mr. Amol Shah | Independent Director |
| Ms. Radhika Dudhat | Independent Director |
| Mr. Abeezar Faizullabhoy | Independent Director |
FAQ
What is the intrinsic value of Camlin Fine Sciences Ltd?
Camlin Fine Sciences Ltd's intrinsic value (as of 08 January 2026) is ₹1071.06 which is 591.01% higher the current market price of ₹155.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹2,971 Cr. market cap, FY2025-2026 high/low of ₹335/113, reserves of ₹871 Cr, and liabilities of ₹2,037 Cr.
What is the Market Cap of Camlin Fine Sciences Ltd?
The Market Cap of Camlin Fine Sciences Ltd is 2,971 Cr..
What is the current Stock Price of Camlin Fine Sciences Ltd as on 08 January 2026?
The current stock price of Camlin Fine Sciences Ltd as on 08 January 2026 is ₹155.
What is the High / Low of Camlin Fine Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Camlin Fine Sciences Ltd stocks is ₹335/113.
What is the Stock P/E of Camlin Fine Sciences Ltd?
The Stock P/E of Camlin Fine Sciences Ltd is 185.
What is the Book Value of Camlin Fine Sciences Ltd?
The Book Value of Camlin Fine Sciences Ltd is 47.3.
What is the Dividend Yield of Camlin Fine Sciences Ltd?
The Dividend Yield of Camlin Fine Sciences Ltd is 0.00 %.
What is the ROCE of Camlin Fine Sciences Ltd?
The ROCE of Camlin Fine Sciences Ltd is 11.0 %.
What is the ROE of Camlin Fine Sciences Ltd?
The ROE of Camlin Fine Sciences Ltd is 15.0 %.
What is the Face Value of Camlin Fine Sciences Ltd?
The Face Value of Camlin Fine Sciences Ltd is 1.00.